Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2017

View Archived Issues

Lysogene's candidate for GM1 gangliosidosis wins FDA rare pediatric disease designation

Telix signs product collaboration and purchase option agreement with Atlab

FDA accepts Ezra's NDA for EZR-104 to treat hypertension and heart failure

Full phase I data reported for novel anti-HIV compound ABX-464

Novo Nordisk initiates first human dose trial of NNC0194-0499

FDA approves Imbruvica for marginal zone lymphoma

Symbiomix Therapeutics submits NDA for Solosec

AbCellera receives grant to discover monoclonal antibodies against Mtb

PhaseBio obtains financing to support study of PB-1046

hERG as a novel glioblastoma survival marker

Cytori to acquire Azaya Therapeutics assets

Discovery of new chemical probe for BRPF proteins for cellular and in vivo studies

EUROSTARS funding to support development of LiPlaCis

FDA approves Rhofade, Allergan's topical treatment for persistent facial erythema

The University of Texas patents novel GLS inhibitors

TP Therapeutics presents new protein kinase inhibitors

FDA acknowledges receipt of NDA for Shire's ADHD drug SHP-465

Lilly identifies novel MetAP2 and DPP IV inhibitors

Cynata and FUJIFILM sign license option agreement

Roche divulges novel DDR1 inhibitors

PharmAthene, Altimmune enter merger agreement

Jilin University and Shanghai Pharmaceuticals Holding identify new JAK inhibitors

FDA approves Trulance for chronic idiopathic constipation

UCB submits sNDA for Briviact in U.S.

EMA awards orphan designation to Abeona Therapeutics' ABO-101

Japanese priority review for regorafenib in second-line treatment of unresectable HCC

Merrimack Pharmaceuticals -- refocused for 2017

Suliqua approved in Europe for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...